Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

Core clinician-reference fields are available or not applicable.

Patients treated with dapagliflozin as part of SGLT2i therapy.

Dapagliflozin

Among them, 57 patients were on dapagliflozin.

Patients treated with empagliflozin as part of SGLT2i therapy.

Empagliflozin

Among them, 50 patients were on empagliflozin.

SGLT2 inhibitors improve atrial conduction time in diabetes

Group B

Patients randomized to receive SGLT2 inhibitors in addition to baseline treatment.

Group A

Fifty patients were randomized to receive SGLT2 inhibitors in addition to baseline treatment (Group A)

Subjects continued with their baseline treatment or were added other medications as needed.

47 subjects continued with their baseline treatment or were added other medications as needed (Group B)

SGLT2 inhibitors improve quality of life in Type 2 diabetes

Available source content was suppressed because validation identified a conflict.

Conventional treatment group

Patients receiving tofogliflozin in addition to ongoing therapy.

Tofogliflozin group

In the tofogliflozin group, 20 mg of tofogliflozin once daily was started in addition to ongoing therapy.

Patients receiving conventional treatment without SGLT2 inhibitors.

In the conventional treatment group, either the dosage of the ongoing therapy was increased, or a concomitant oral glucose-lowering drug (excluding any SGLT2 inhibitor) was added 12 weeks after randomization.

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

SGLT2 inhibitors × HbA1c

Available supporting studies

SGLT2 inhibitors improve atrial conduction time in diabetes

SGLT2 inhibitors improve quality of life in Type 2 diabetes

Tofogliflozin improves weight loss in type 2 diabetes patients with obesity